Xerox Adaptive CMYK+ Kit for Xerox Versant Expands Color Palette to More Than a Million
Xerox announced the Xerox Adaptive CMYK+ Kit for Xerox Versant®, the print market’s first adaptive technology kit that adds seven specialty colors to an existing production press, enabling instant digital print enhancements. The kit transforms a four-color Xerox Versant® 180 Press into an 11-color Beyond CMYK press capable of creating a million color hues and shades by adding gold, silver, white, clear and fluorescent colors of yellow, magenta and cyan.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200707005242/en/
The print market’s first adaptive technology kit that adds seven specialty colors to an existing production press. (Photo: Business Wire)
Digital enhancement of print is projected to be a $25 billion market¹, but access to that opportunity usually requires a capital investment in a new press with the ability to print Beyond CMYK. The Xerox Adaptive CMYK+ Kit for Versant gives print providers the ability to simply swap out toners to print colors and enhancements that increase profitability and deliver higher margins without needing a new press.
“The Versant CMYK+ Adaptive Kit delivers what print providers need – the ability to provide higher value offerings without major investment,” says Marybeth Gilbert, vice president and general manager, Production Business, Xerox. “The Versant kit further expands Xerox’s market leading Beyond CMYK portfolio, providing our customers opportunity for digital print enhancements from large volume print shop, to light production and into the office space.”
According to Keypoint Intelligence, print providers can increase profit margins on digital enhancements between 50 and 400 percent versus ordinary print. Also, promotional printing such as marketing collateral, brochures, business cards, and signage is the most common application category for embellishments². The Versant 180 is uniquely suited and designed for such uses so print providers can easily convert, enhance and charge more for ordinary jobs.
The Xerox Adaptive CMYK+ Kit for Xerox Versant has three options: the Xerox Vivid Kit (gold, silver, white and clear), Xerox Fluorescent Kit (cyan, magenta and yellow) – or the combination Xerox Vivid + Fluorescent Kit for all 11 colors. The adaptive kit works with EFI DFE versions of the Versant 180 and Versant 180 with Performance Package.
Availability:
The Xerox Adaptive CMYK+ Kit for Xerox Versant is available now for order taking in both EMEA and the Americas. The kit will be available for delivery in EMEA on July 15, 2020 and in the Americas on August 17, 2020.
About Xerox
Xerox Holdings Corporation makes every day work better. We are a workplace technology company building and integrating software and hardware for enterprises large and small. As customers seek to manage information across digital and physical platforms, Xerox delivers a seamless, secure and sustainable experience. Whether inventing the copier, Ethernet, the laser printer or more, Xerox has long defined the modern work experience. Learn how that innovation continues at xerox.com.
¹ Keypoint Intelligence/Infotrends, “Beyond CMYK: The Use of Special Effects in Digital Printing”
² Keypoint Intelligence/Infotrends, “Market Opportunities for CMYK+”
Note: To receive RSS news feeds, visit https://www.news.xerox.com. For open commentary, industry perspectives and views, visit http://twitter.com/xerox , http://www.facebook.com/XeroxCorp, https://www.instagram.com/xerox/, http://www.linkedin.com/company/xerox, http://www.youtube.com/XeroxCorp.
Xerox® is a trademark of Xerox in the United States and/or other countries.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200707005242/en/
Contact information
Gary Walker, Xerox, +1-585-427-1679, Gary.Walker@xerox.com
Sonia Panchal, Xerox, +44 (0)7713 191581, sonia.panchal@xerox.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Lilac and Traxys Announce Binding 10-Year Offtake Agreement for Great Salt Lake Lithium Production12.1.2026 14:00:00 EET | Press release
Lilac Solutions, a leading provider of direct lithium extraction technology, and Traxys North America, a leading global physical trader and merchant in metals and natural resources, today announced a binding 10-year offtake agreement for lithium carbonate produced at Lilac's Great Salt Lake facility in Utah. The agreement represents a major milestone in advancing the project toward construction and establishes a clear commercial pathway for one of the nearest-term domestic lithium projects in the United States. Under the terms of the definitive agreement, Traxys will purchase 50,000 tonnes of lithium carbonate over a 10-year period, representing 100% of the planned Phase 1 production capacity. The agreement is take-or-pay, with agreed pricing mechanisms linked to market indices. The Great Salt Lake Phase 1 facility is designed to produce 5,000 tonnes per annum of battery-grade lithium carbonate, which would nearly double current U.S. lithium carbonate production. The project leverages
Enginzyme and AGC Create Scalable Process for Key mRNA Ingredient12.1.2026 07:00:00 EET | Press release
At the mRNA Health conference in Berlin, enginzyme and AGC Inc. presented a scalable process to produce a key mRNA vaccine and therapy ingredient, N1-methylpseudouridine-5'-triphosphate (m¹ΨTP). The rapid growth of mRNA-based vaccines and therapeutics has driven significant demand for modified nucleotides like m¹ΨTP, which enhances mRNA stability and expression, while reducing immunogenicity. Enginzyme is a deep-tech company delivering optimized biomanufacturing solutions through cell-free enzyme engineering technology. AGC Inc. is a leading global player in fields spanning from architectural glass to chemicals and life science. AGC Inc. provides services in a wide range of life science fields, from synthetic pharmaceuticals and agrochemicals, to biopharmaceuticals and leading-edge cell and gene therapies, as well as messenger RNAs. The presentation in November detailed the latest collaboration between the companies, with a focus on the biomanufacturing of nucleotides for mRNA therapy,
Ant International Partners with Google’s Universal Commerce Protocol to Expand AI Capabilities12.1.2026 03:15:00 EET | Press release
Ant International, a leading global payment, digitisation, and financial technology provider, is collaborating on the launch of Google’s Universal Commerce Protocol (UCP), a new open standard for agentic commerce that works across the entire shopping journey — from discovery and buying to post-purchase support. UCP establishes a common language for agents and systems to operate together across consumer surfaces, businesses, and payment providers to enable commerce. So instead of requiring unique connections for every individual agent, UCP enables all agents to interact easily. UCP is built to work across verticals and is compatible with existing industry protocols like Agent2Agent (A2A), Agent Payments Protocol (AP2), and Model Context Protocol (MCP). “For agentic commerce to scale, it’s critical for the industry to align on a common set of standards. We are proud to have Ant International endorse the Universal Commerce Protocol as the foundation for that future,” said Ashish Gupta, VP
Torq Secures $140M Series D at $1.2B Valuation to Lead the AI SOC and Agentic AI Era11.1.2026 18:59:00 EET | Press release
Torq, the established Agentic AI security operations pioneer, today announced it has closed a massive $140 million Series D funding round, propelling its valuation to $1.2 billion and total funding to $332M. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260112510774/en/ Led by Merlin Ventures—a leading cybersecurity fund renowned for its deep access to the U.S. commercial and Public Sector markets—with participation from all existing investors, including Evolution Equity Partners, Notable Capital, Bessemer Venture Partners, Insight Ventures Partners, and Greenfield Partners, this capital injection is a definitive investment in the future of security. Torq is driving the industry’s critical shift: the complete transformation of the Security Operations Center (SOC) through battle-tested AI Agents at enterprise scale. The new funds will accelerate the adoption of the Torq AI SOC Platform, the only end-to-end solution built on
Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 14:00:00 EET | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreement were not disclosed. “This new agreement builds upon our recent co-development collaboration with Acepodia, which has focused on the evaluation and selection
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom